Abstract
The development of a new therapeutic agent for human use is a complex, highly regulated, risky, and expensive process which, in the case of insomnia and other sleep disorders, presents some special challenges typical of this group of diseases. The development of a new therapeutic agent consists of a series of Nonclinical and clinical phases in which the new drug candidate has to demonstrate, among other things, a favorable benefit/risk ratio in the treatment of a given disease before receiving market authorization and be used to treat patients. In the Nonclinical development phase chemical development, formulation development, analytical methods development, pharmacology development, pharmacokinetic development, and Nonclinical safety evaluation of the new drug candidate are carried out. The main goal of these studies, conducted both in vitro and in vivo in laboratory animals, is to collect sufficient information to authorize the evaluation of the new therapeutic agent in humans. The clinical development phase of a new therapeutic agent consists of several steps in which the new drug candidate is administered to humans in a stepwise progression starting with administration to a reduced number of healthy volunteers and then progressing to patients in order to assess its safety and efficacy. In addition, in the case of hypnotics, specific points of concerns such as development of tolerance, potential for drug abuse, interaction with other drugs, and next-day performance should also be addressed and evaluated promptly and properly. Several guidelines issued by regulatory agencies are available to guide investigators throughout the entire development process and should be consulted to correctly design and execute the individual studies of the development plan. Nevertheless, during the development of new therapeutic agents for insomnia and other sleep disorders, specific issues can arise which are not covered by the available guidelines. Therefore, it is always highly advisable to consult with regulatory agencies on how to address these specific points. A better understanding on the drug regulatory framework and rules can maximize the chances of a successful development of a new therapeutic agent for treatment of insomnia and other sleep disorders.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
After this book went to press, on Aug 13th 2014, the US Food and Druf Administration approved Suvorexant (Belsomra) tablets to treat difficulty in falling and stying alseep (insomnia). Suvorexant is the first approved drug of the orexin antagonists class.
References
Bain KT (2006) Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 4:168–192
Bateson AN (2002) Basic pharmacologic mechanism involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 1:5–21
Bodrogi J, Kaló Z (2010) Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol 159:1367–1373
Cardario B et al (2011) Drugs and the risk of falling. Guidance document. http://www.health.gov.bc.ca/prevention/pdf/medications-and-the-risk-of-falling.pdf
Chalkidou K (2009) Comparative effectiveness review within the U.K.’s National Institute for Health and Clinical Excellence. The Commonwealth fund 59: pub 1296
Clare G (2012) The in-vitro mammalian chromosomal aberration test. Methods Mol Biol 817:69–91
Costantino HR, Illum L, Brandt G et al (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24
De la Herrán-Arita AK, Druken-Colin R (2012) Models for narcolepsy with catalepsy drug discovery. Expert Opin Drug Discov 7:152–164
de Lecea L, Huerta R (2014) Hypocretin (orexin) regulation of sleep-to-wake transition. Front Pharmacol 5:16
de Lecea L, Kilduff TS, Peyron C et al (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322–327
Deacon RM (2013) Measuring the strength of mice. J Vis Exp 76:2610
DiMasi JA, Feldman J, Seckler A et al (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87:272–277
Doering S, Boeckmann JA, Hugger S et al (2008) Ambulatory polysomnography for the assessment of sleep bruxism. J Oral Rahabil 35:572–576
Equihua AC, De la Herrán-Arita AK, Drucker-Colin R (2013) Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 4:1–10
European Medicines Agency (EMA) (1994) Pharmacokinetics and metabolic studies in the safety evaluation of new medicinal products in animals. 3BS 11A
European Medicines Agency (EMA) (2001) Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00
European Medicines Agency (EMA) (2006) Guideline on the non-clinical investigation of the dependence potential of medicinal products. EMEA/CHMP/SWP/94227/2004
European Medicines Agency (EMA) (2007) Guideline on strategy to identify and mitigate risks for first in human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07
European Medicinal Agency (EMA) (2008) Guidelines on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. EMEA/CHMP/203927/2005
European Medicines Agency (EMA) (2010a) Guideline on repeated dose toxicity. CPMP/SWP/1042/99 Rev 1 Corr
European Medicines Agency (EMA) (2010b) Reflection paper on non-clinical evaluation of drug-induced liver injury (DILI). EMEA/CHMP/SWP/150115/2006
European Medicines Agency (EMA) (2011) Medicinal products for the treatment of insomnia. CHMP/16274/2009 Rev 1
European Medicines Agency (EMA) (2014) Guideline on medicinal products for the treatment of insomnia. EMA/213031/2014
Food and Drug Administration (1977) Guideline for the clinical evaluation of hypnotic drugs
Food and Drug Administration (2002) Guidance for industry immunotoxicology evaluation of investigational new drugs
Food and Drug Administration (2005a) Good pharmacovigilance practices and pharmacoepidemiologic assessment
Food and Drug Administration (2005b) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers
Food and Drug Administration (2006) Exploratory IND studies
Food and Drug Administration (2008) Safety testing of drug metabolites
Food and Drug Administration (2010) Assessment of abuse potential of drugs
Food and Drug Administration (2011) Reproductive and developmental toxicities–integrating study results to assess concern
Food and Drug Administration (2013) FDA-approved drugs to treat sleep disorders. J Psychosoc Nurs Ment Health Serv 51:9–10
Greenblatt DJ, Roth T (2012) Zolpidem for insomnia. Expert Opin Pharmacother 13:879–893
Griffiths RR, Johnson NW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(S9):31–41
Gunja N (2013) In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol 9:163–171
Hajak G, Müller WE, Wittchen HU et al (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378
Heit HA (2003) Addiction, physical dependence, and tolerance: precise definition to help clinicians evaluate and treat chronic patients. J Pain Palliat Care Pharmacother 17:15–29
Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interaction with zopiclone, zolpidem and zaleplon. CNS Drugs 17:513–532
ICH Harmonised Tripartite Guideline (1994a) Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies. Guideline S3A
ICH Harmonised Tripartite Guideline (1994b) Guidance for repeated dose tissue distribution studies. Guideline S3B
ICH Harmonised Tripartite Guideline (1995) Guideline on the need for carcinogenicity studies of pharmaceuticals. Guideline S1A
ICH Harmonised Tripartite Guideline (1996) Stability for new dosage forms. Guideline Q1C
ICH Harmonised Tripartite Guideline (1998) Duration of chronic testing in animals (rodent and non rodent toxicity testing). Guideline S4
ICH Harmonised Tripartite Guideline (2005a) Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. Guideline S5(R2)
ICH Harmonised Tripartite Guideline (2005b) Immunotoxicity studies for human pharmaceuticals. Guideline S8
ICH Harmonised Tripartite Guideline (2000) Safety pharmacology studies for human pharmaceuticals. Guideline S7A
ICH Harmonised Tripartite Guideline (2009) Guideline on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Guideline M3(R2)
ICH Harmonised Tripartite Guideline (2011) Guideline on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. Guideline S2(R1)
ICH Harmonised Tripartite Guideline (2012) Development and manufacture of drug substance (chemical entities and biotechnological/biological entities). Guideline Q11
Ilomäki J, Paljärvi T, Korhonen MJ et al (2013) Prevalence of concomitant use of alcohol and sedative-hypnotic drugs in middle and older aged persons: a systematic review. Ann Pharmacother 47:257–268
International Society for Pharmacoeconomics and Outcome Research. Pharmacoeconomic guidelines around the world. www.ispor.org/peguidelines/index.asp
Johannesen L, Vicente J, Gray RA et al (2014) Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther 95:501–508
Kamel NS, Gammack JK (2006) Insomnia in the elderly: cause, approach, and management. Am J Med 119:463–469
Kanbayashi T, Inoue Y, Chiba S et al (2002) CSF hypocretin-1 (orexin A) concentrations in narcolepsy with and without catalepsy and idiopathic hipersomnia. J Sleep Res 11:91–93
Katchman AN, Koerner J, Tosaka T et al (2005) Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and non torsadogenic drugs. J Pharmacol Exp Ther 316:1098–1106
Kolla BP, Lovely JK, Mansukhani MP et al (2013) Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 8:1–6
Kryger MH, Roth T, Dement WC (eds) (2011) Principles and practice of sleep medicine, 5th edn. Elsevier Saunders, St. Louis, MO
Krystal AD, Benca RM, Kilduff TS (2013) Understanding the sleep-wake cycle: sleep, insomnia and the orexin system. J Clin Psychiatry S1:3–20
López-Muñoz F, Ucha-Udabe R, Alamo C (2005) The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 1:329–343
Martelmans K, Zeiger E (2000) The Ames salmonella/microsome mutagenicity assay. Mutat Res 455:29–60
Mets MA, Volkerts ER, Oliver B (2010) Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 14:259–267
Meyer OA, Tilson HA, Byrd WC (1979) A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1:233–236
Mignot E, Lammers GJ, Ripley B et al (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553–1562
Milić M, Divljaković J, Rapalli S et al (2012) The role of α1 and α5 subunits containing GABAA receptors in motor impairment induced by benzodiazepine in rats. Behav Pharmacol 23:191–197
Mould R, Brown J, Marshall FH et al (2014) Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br J Pharmacol 171:351–363
Nakamura M, Kanbayashi T, Sugiura T et al (2010) Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. J Sleep res 20:45–49
Nishino S, Ripley B, Overeem S et al (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40
Noble RE (2003) Drug therapy in the elderly. Metabolism 52(S2):27–30
Nordmann H (1985) Grip strength test and infrared thermometry as non-invasive methods to complement acute toxicity data in mice. Arch Toxicol Suppl 8:435–441
Nutt DJ, Sathl SM (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 24:1601–1612
O’brien CP (2005) Benzodiazepines use, abuse and dependence. J Clin Psychiatry 2:28–33
Obayashi K, Araki T, Nakamura K et al (2013) Risk of falling and hypnotic drugs: retrospective drugs of inpatients. Drugs R D 13:159–164
OECD (1997) In-vitro mammalian chromosomal Aberration test. Test No: 473
Owen RT (2009) Novel zolpidem formulations. Drugs Today 45:395–400
Owens JA (2006) Pediatric insomnia. Sleep Med Clin 1:423–435
Rabbani M, Wright EJ, Little HJ (1995) Tolerance of competitive NMDA antagonists, but not cross tolerance with barbiturates. Pharmacol Biochem Behav 50:9–15
Rowlett JK, Platt DM, Lelas S et al (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci USA 102:915–920
Sakurai T, Amemiya A, Ishii M et al (1998) Orexin and orexin receptors: a family of hypothalamic neuropeptides and G-protein coupled receptors that regulate feeding and feeding behavior. Cell 4:573–585
Saunders JB (1986) Drugs and alcohol—their interactions and how to avoid them. Curr Ther 27:31–53
Sellayah D, Sikder D (2013) Food for thought: understanding the multifaceted nature of orexins. Endocrinology 154:2990–3999
Stephenson T (2005) How children’s responses to drugs differ from adults. Br J Clin Pharmacol 59:670–673
Toth LA, Bhargava P (2013) Animal models of sleep disorders. Comp Med 63:91–104
Uzun S, Kozumplik O, Jakovljevic M et al (2010) Side effects of treatment with benzodiazepines. Psychiatr Danub 22:90–93
Vinkers CH, Oliver B (2012) Mechanism underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci 2012:416864
Wang D, Wong KK, Dungan GC et al (2008) The validity of wrist actimetry assessment of sleep with and without sleep apnea. J Clin Sleep Med 4:450–455
Wick JY (2013) The history of benzodiazepines. Consult Pharm 28:538–548
Winrow CJ, Renger JJ (2014) Discovery and development of orexin receptor antagonists as therapeutic for insomnia. Br J Pharmacol 17:283–293
Zisapel N (2012) Drugs for insomnia. Expert Opin Emerg Drugs 17:299–317
Zosel A, Osterberg EC, Mycyk MB (2011) Zolpidem miuse with other medications or alcohol frequently results in intensive cure unit admission. Am J Ther 18:305–208
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Martin, G., Guglietta, A. (2015). Development of New Therapeutical Agents for Treatment of Insomnia and Other Sleeps Disorders. In: Guglietta, A. (eds) Drug Treatment of Sleep Disorders. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-11514-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-11514-6_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11513-9
Online ISBN: 978-3-319-11514-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)